Evidence map›Paper›PMID 34306136›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2021

Siba Shanak, Najlaa Bassalat, Raghad Albzoor, Sleman Kadan, Hilal Zaid

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Therapeutic Potential of OzonatedPharmaceuticals (Basel, Switzerland) · 2025
    Article
  3. Review
  4. Frontiers in pharmacology · 2024
    Article
  5. Review
  6. Bioprospecting of FivePharmaceuticals (Basel, Switzerland) · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Siba ShanakFaculty of Sciences, Arab American University, P.O Box 240, Jenin, State of Palestine.ORCID https://orcid.org/0000-0002-2987-6079
Najlaa BassalatFaculty of Sciences, Arab American University, P.O Box 240, Jenin, State of Palestine.ORCID https://orcid.org/0000-0003-2292-1591
Raghad AlbzoorFaculty of Sciences, Arab American University, P.O Box 240, Jenin, State of Palestine.ORCID https://orcid.org/0000-0003-1893-1949
Sleman KadanQasemi Research Center, Al-Qasemi Academic College, P.O Box 124, Baqa-El-Gharbia 30100, Israel.ORCID https://orcid.org/0000-0002-0631-0435
Hilal ZaidFaculty of Medicine, Arab American University, P.O Box 240, Jenin, State of Palestine.ORCID https://orcid.org/0000-0002-1562-8031
Arab American University · PSAl-Qasemi Academic College of Education · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus is a metabolic disease that predominates, nowadays. It causes hyperglycemia and consequently major health complications. Type II diabetes is the most common form and is a result of insulin resistance in the target tissues. To treat this disease, several mechanisms have been proposed. The most direct route is via inhibiting the intestinal enzymes, e.g.,

Identifiers

PMID34306136
PMCPMC8279857
OpenAlexW3182306611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.